245 results on '"Tokuda, Shinsaku"'
Search Results
2. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
3. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
4. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
5. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
6. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
7. Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy
8. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
9. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
10. Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
11. Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
12. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
13. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
14. Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients
15. Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer
16. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
17. Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant
18. Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells.
19. Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.
20. Figure S7 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
21. Data from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
22. Supplementary Table2 from Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
23. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
24. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer.
25. Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
26. MO57-6 Comprehensive genomic profiling is effective in determining treatment decisions for advanced solid tumors patients
27. Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
28. Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
29. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
30. Abstract 4015: EGFR activation via c-Jun axis promotes adaptive resistance to third generation ALK-TKI lorlatinib in ALK-rearranged non-small cell lung cancer cells
31. Abstract 6222: Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer
32. Abstract 410: Tumor heterogeneity via AXL activation on primary resistance to EGFR tyrosine kinase inhibitors in EGFR mutated lung cancer
33. Abstract 594: Effects of interstitial pressure on lung cancer cells
34. Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
35. Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
36. Localized expression and role of full-length growth differentiation factor 15 in non-small cell lung cancer
37. Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer
38. Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer
39. Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
40. Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer
41. Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study
42. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
43. Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report
44. The impact of a large-scale natural disaster on patients with chronic obstructive pulmonary disease: The aftermath of the 2011 Great East Japan Earthquake
45. Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
46. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR ‐T790M mutation in non‐small cell lung cancer cells
47. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer
48. Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients
49. Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
50. Combinatorial expression of claudins in the proximal renal tubule and its functional consequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.